A trial looking at pertuzumab, trastuzumab and an aromatase inhibitor for breast cancer that has spread (PERTAIN)
Cancer type:
Status:
Phase:
This trial looked at pertuzumab with trastuzumab and a type of hormone therapy called an aromatase inhibitor.
It was for women whose breast cancer had 
and . And had spread to surrounding tissue or to another part of the body.
The trial was open for people to join between 2012 and 2014. The trial team published results in 2018.
More about this trial
Trastuzumab (Herceptin) is a type of targeted cancer treatment called a monoclonal antibody. It blocks a receptor called HER2 on cancer cells. This helps stop the cancer cell from growing.
Aromatase inhibitors (AIs) are a type of hormone therapy. They lower the level of oestrogen in the body. This can also help stop the cancer growing.
The researchers already knew that trastuzumab and an AI works for breast cancer that:
- is locally advanced or has spread to another part of the body
- has HER2 receptors and hormone receptors
They wanted to find out whether it was useful to have pertuzumab as well. Pertuzumab is also a monoclonal antibody. It blocks the HER2 receptor, but in a different way to trastuzumab.
The main aims of this trial were to find out:
- how well pertuzumab, trastuzumab and an AI worked for this type of breast cancer
- more about the side effects
Summary of results
As part of our editorial policy, we ask someone from the team who ran the trial to check the information we have written before we add it to our website.
Unfortunately, there was no one available from the trial team to check the summary of results for this trial for us. This means we are unable to include a results summary on this page.
There is more information about this trial in the link below.
Please note, this information is not in plain English. It has been written for health care professionals and researchers.
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
M Rimawi and others
Journal of Clinical Oncology, 2018. Volume 36, Issue 28.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Peter Schmid
Supported by
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
